Quintiles firmly believes that biosimilar products pose a unique and important opportunity to improve the access to and affordability of new medicines around the globe. Our recent white paper stresses that successful biosimilar companies will be those who collapse their clinical, commercial, and regulatory thinking into a streamlined cohesive function as they proceed with developing biosimilars.